We are a team of scientists, innovators and entrepreuners

Dr. Danuta Jeziorska

Academic Founder, Executive Director & CEO

Danuta is a Founder and CEO of Nucleome Therapeutics and an Honorary Senior Scientist at the University of Oxford. Previously, she co-founded Innovation Forum Oxford, for which she was recognised as one of the Movers and Shakers in BioBusiness in 2018. Her scientific expertise lies in decrypting how genes are regulated, a field which she has been working on over the last 14 years.

Prof. Jim Hughes

Academic Founder, Non-Executive Director

Jim is a Founder of Nucleome Therapeutics and a Professor of Gene Regulation at the University of Oxford. His research combines experimental, computational and machine learning based approaches in order to functionally interpret the non-coding genome and its role in human diseases. His group has developed numerous cutting-edge technologies and tools used world-wide.

Dr. James Davies

Academic Founder

James is a Founder of Nucleome Therapeutics and Associated Professor at the University of Oxford. His expertise lies in developing novel sequencing-based assays and computational approaches for understanding how the genome functions. He is also a consultant haematologist with an interest in stem cell transplantation and cellular therapy and a fully qualified intensive care physician

Dr. Danuta Jeziorska

Academic Founder, Executive Director & CEO

Danuta is a Founder and CEO of Nucleome Therapeutics and an Honorary Senior Scientist at the University of Oxford. Previously, she co-founded Innovation Forum Oxford, for which she was recognised as one of the Movers and Shakers in BioBusiness in 2018. Her scientific expertise lies in decrypting how genes are regulated, a field which she has been working on over the last 14 years.

Prof. Jim Hughes

Academic Founder, Non-Executive Director

Jim is a Founder of Nucleome Therapeutics and a Professor of Gene Regulation at the University of Oxford. His research combines experimental, computational and machine learning based approaches in order to functionally interpret the non-coding genome and its role in human diseases. His group has developed numerous cutting-edge technologies and tools used world-wide.

Dr. Jonathan Hepple

Non-Executive Director & OSI Advisor

Jon is a co-founder of Rosetta Capital Limited, a venture capital firm focused on life science and medical technology sectors, where he has served as a Partner since January 2009. He has more than twenty years of investment experience in the life sciences industry. He started his investment career at Rothschild Asset Management before co-founding BioScience Managers Ltd in 2001. He has also served as a partner of Seroba Life Sciences Limited. Dr Hepple has held board director and observer roles in portfolio companies such as Aprea Therapeutics, Covagen AG, Opsona Therapeutics Ltd., Catalyst Biosciences, Glycomimetics, Inc., NovImmune SA and Tranzyme Pharma. He received his PhD from Cambridge University for cancer research.

Dr. James Davies

Academic Founder

James is a Founder of Nucleome Therapeutics and Associated Professor at the University of Oxford. His expertise lies in developing novel sequencing-based assays and computational approaches for understanding how the genome functions. He is also a consultant haematologist with an interest in stem cell transplantation and cellular therapy and a fully qualified intensive care physician

Matt Carpenter

Observer

Matt obtained a first-class honours degree in Biomedical Sciences from the University of the West of England, Bristol and subsequently a PhD from Imperial College in immunology (1999). Following three years as a post-doctoral research fellow at Imperial College, and a short spell as a technical adviser with Invitrogen, Matt entered the technology transfer profession in 2004 as the Intellectual Property Rights Manager within the Research and Knowledge Exchange Services at the University of Strathclyde, Glasgow. Matt joined Oxford University Innovation in 2011 and is currently a Principal Licensing & Ventures Manager (pharma and biotech team) in the Licensing & Ventures Team.

Dr. Eliot Forster

CEO of F-Star, former CEO of Immunocore

Eliot has more than 28 years of experience in the pharmaceutical and biotechnology industry and previously served as Chief Executive Officer of Immunocore, Creabilis Therapeutics and Solace Pharmaceuticals. Other previous roles included Head of Development and Operations for the EU and Asia at Pfizer. Eliot has held a number of non-executive Director roles and is currently non-executive Chairman of Avacta plc. He is an Honorary Visiting Professor of the Pharmacology and Physiology Department at the University of Liverpool and an Honorary Professor at the University of Pavia, a Board member of OSCHR (Office for Strategic Coordination of Health Research) and the National Genomics Board. He holds a PhD from University of Liverpool and an MBA from Henley Management College.